EUVIMEDEUVIMED entdecken
Crossref

Effect of food and polymorphisms in SLCO2B1 , CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers

Yixin Hu iD, Jianyuan Wu, Bingyu Cheng, Rongli You, Xueyan Yin, Guiying Chen, Ling Yang, Yang Zhang, Luqin Si, Hongliang Jiang, Yongjun Zhang, Jianying Huang und 1 weitere

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.15883 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Yixin Hu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Androstenes, Organic Anion Transporters, Cytochrome P-450 CYP3A. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Hubei Province Major Basic Research Development Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Abiraterone acetate, a prodrug of abiraterone (ABI), provides an efficient therapeutic option for metastatic castration‐resistant prostate cancer patients. ABI undergoes extensive metabolism in vivo and is transformed into active metabolites Δ 4 ‐abiraterone and 3‐keto‐5α‐abiraterone as well as inactive metabolites abiraterone sulfate and abiraterone N‐oxide sulfate. We aimed to examine the effect of polymorphisms in SLCO2B1 , CYP3A4 and UGT1A4 on the pharmacokinetics of ABI and its metabolites.

Methods

In this study, 81 healthy Chinese subjects were enrolled and divided into 2 groups for fasted ( n = 45) and fed ( n = 36) studies. Plasma samples were collected after administering a 250 mg abiraterone acetate tablet followed by liquid chromatography–tandem mass spectrometry analysis. Genotyping was performed on a MassARRAY system. The association between SLCO2B1 , CYP3A4 , UGT1A4 genotype and pharmacokinetic parameters of ABI and its metabolites was assessed.

Results

Food effect study demonstrated high fat meal remarkedly increased systemic exposure of ABI and its metabolites. The geometric mean ratio and 90% confidence interval of area under the plasma concentration–time curve from time 0 to the time of the last quantifiable concentration (AUC 0‐t ) and maximum plasma concentration (C max ) of ABI in fed state vs . fasted state were 351.64% (286.86%–431.04%) and 478.45% (390.01%–586.94%), respectively, while the corresponding results were ranging from 145.11% to 269.42% and 150.10% to 478.45% for AUC 0‐t and C max of ABI metabolites in fed state vs . fasted state, respectively. The SLCO2B1 rs1077858 had a significant influence on AUC 0‐t and C max , while 7 other SLCO2B1 variants prolonged half‐life of ABI under both fasted and fed conditions. As for ABI metabolites, the systemic exposure of Δ 4 ‐abiraterone, abiraterone sulfate and abiraterone N‐oxide sulfate as well as the elimination of 3‐keto‐5α‐abiraterone were significantly affected by SLCO2B1 polymorphisms. Polymorphisms in CYP3A4 and UGT1A4 did not significantly affect pharmacokinetics of ABI and its metabolites.

Conclusion

Polymorphisms in SLCO2B1 were significantly related to the pharmacokinetic variability of ABI and its metabolites under both fasted and fed conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrostenesOrganic Anion TransportersCytochrome P-450 CYP3APharmacokineticsHumansGlucuronosyltransferaseProstatic NeoplasmsPolymorphism, Single NucleotideEast Asian PeopleMaleVolunteersAdultFastingFood

Stichwörter der Autor:innen

SLCO2B1abirateronepharmacokineticspolymorphism

Substanzen

abirateroneAndrostenesSLCO2B1 protein, humanOrganic Anion TransportersCYP3A4 protein, humanCytochrome P-450 CYP3Abilirubin glucuronoside glucuronosyltransferaseGlucuronosyltransferase

Autor:innen und Institutionen

  • Department of Pharmaceutics, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Department of Pharmacology, Beijing Zhendong Pharmaceutical Research Institute Co, Ltd, Beijing, China.
  • The Third Affiliated Hospital of School of Medicine, Shihezi University, Shihezi, China.
  • Wuhan Hongren Biopharmaceutical Inc., Wuhan, China.
  • Wuhan Hongzhi Biomedical Inc., Wuhan, China.

ORCID-Profile: Yixin Hu

Förderung

  • Hubei Province Major Basic Research Development Program

Zitieren

APA

Hu, Y., Wu, J., Cheng, B., You, R., Yin, X., Chen, G., Yang, L., Zhang, Y., Si, L., Jiang, H., Zhang, Y., Huang, J., & Huang, J. (2024). Effect of food and polymorphisms in SLCO2B1 , CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15883

Vancouver

Hu Y, Wu J, Cheng B, You R, Yin X, Chen G, et al. Effect of food and polymorphisms in SLCO2B1 , CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.15883

BibTeX
@article{Hu2024,
  author = {Hu, Yixin and Wu, Jianyuan and Cheng, Bingyu and You, Rongli and Yin, Xueyan and Chen, Guiying and Yang, Ling and Zhang, Yang and Si, Luqin and Jiang, Hongliang and Zhang, Yongjun and Huang, Jianying and Huang, Jiangeng},
  title = {Effect of food and polymorphisms in SLCO2B1 , CYP3A4 and UGT1A4 on pharmacokinetics of abiraterone and its metabolites in Chinese volunteers},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.15883}
}
Kostenlos starten →